SG11201705116SA - Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof - Google Patents
Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereofInfo
- Publication number
- SG11201705116SA SG11201705116SA SG11201705116SA SG11201705116SA SG11201705116SA SG 11201705116S A SG11201705116S A SG 11201705116SA SG 11201705116S A SG11201705116S A SG 11201705116SA SG 11201705116S A SG11201705116S A SG 11201705116SA SG 11201705116S A SG11201705116S A SG 11201705116SA
- Authority
- SG
- Singapore
- Prior art keywords
- tnf
- receptor binding
- necrosis factor
- tumor necrosis
- binding molecules
- Prior art date
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 102000003390 tumor necrosis factor Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562105323P | 2015-01-20 | 2015-01-20 | |
PCT/US2016/014153 WO2016118641A1 (en) | 2015-01-20 | 2016-01-20 | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201705116SA true SG11201705116SA (en) | 2017-08-30 |
Family
ID=56417700
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201705116SA SG11201705116SA (en) | 2015-01-20 | 2016-01-20 | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
SG10202001779UA SG10202001779UA (en) | 2015-01-20 | 2016-01-20 | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202001779UA SG10202001779UA (en) | 2015-01-20 | 2016-01-20 | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (4) | US10689449B2 (sl) |
EP (2) | EP3247728B1 (sl) |
JP (3) | JP7179464B2 (sl) |
KR (1) | KR102435324B1 (sl) |
CN (1) | CN107207601A (sl) |
AU (2) | AU2016209324B2 (sl) |
CA (1) | CA2972990A1 (sl) |
DK (1) | DK3247728T3 (sl) |
ES (1) | ES2806500T3 (sl) |
HU (1) | HUE051013T2 (sl) |
IL (3) | IL308212A (sl) |
NZ (1) | NZ732922A (sl) |
PL (1) | PL3247728T3 (sl) |
PT (1) | PT3247728T (sl) |
SG (2) | SG11201705116SA (sl) |
SI (1) | SI3247728T1 (sl) |
WO (1) | WO2016118641A1 (sl) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2922830A1 (en) | 2013-09-05 | 2015-04-16 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
CN105992772A (zh) | 2014-02-10 | 2016-10-05 | Igm生命科学股份有限公司 | IgA多特异性结合分子 |
SI3560954T1 (sl) | 2014-04-03 | 2021-11-30 | Igm Biosciences, Inc. | Spremenjena J-veriga |
ES2806500T3 (es) | 2015-01-20 | 2021-02-17 | Igm Biosciences Inc | Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas |
IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | CD20 binding compounds and their uses |
EP3274051A4 (en) | 2015-03-25 | 2018-08-22 | IGM Biosciences A/S | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
JP6811723B2 (ja) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 |
CN108463245A (zh) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j链的结合分子 |
DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
HUE055972T2 (hu) | 2016-05-09 | 2022-01-28 | Igm Biosciences Inc | Anti-PD-L1 antitestek |
WO2018017889A1 (en) * | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
AU2017308734A1 (en) * | 2016-08-12 | 2019-02-14 | Janssen Biotech, Inc. | Fc engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them |
EP3360898A1 (en) * | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
CA3058825A1 (en) | 2017-04-06 | 2018-10-11 | Universitat Stuttgart | Tumor necrosis factor receptor (tnfr) binding protein complex with improved binding and bioactivity |
EP3607091A4 (en) | 2017-04-07 | 2021-01-20 | IGM Biosciences, Inc. | MODIFIED HUMAN CONSTANT IGM REGIONS FOR THE MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
CN108251443A (zh) * | 2018-01-23 | 2018-07-06 | 深圳市人民医院 | 一种tnfrsf10c重组质粒、制备方法及其应用 |
WO2019157772A1 (zh) * | 2018-02-13 | 2019-08-22 | 和元生物技术(上海)股份有限公司 | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 |
KR20200123782A (ko) * | 2018-02-26 | 2020-10-30 | 아이쥐엠 바이오사이언스 인코포레이티드 | 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도 |
MX2020009069A (es) | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
CA3148881A1 (en) * | 2019-08-02 | 2021-02-11 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Anti-tnfr2 antibody and use thereof |
WO2021202863A1 (en) * | 2020-04-02 | 2021-10-07 | Promab Biotechnologies, Inc. | Human ror-1 antibody and anti-ror-1-car-t cells |
CN115485299A (zh) | 2020-04-22 | 2022-12-16 | Igm生物科学股份有限公司 | Pd-1激动剂多聚结合分子 |
WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
JP7203870B2 (ja) | 2021-01-18 | 2023-01-13 | イビデン株式会社 | 組電池用熱伝達抑制シート及び組電池 |
CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
Family Cites Families (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
GB9015908D0 (en) | 1990-07-19 | 1990-09-05 | Celltech Ltd | Multivalent immunoglobulin |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
DE69333950T2 (de) | 1992-05-18 | 2006-08-17 | Genentech, Inc., South San Francisco | Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden |
DE122009000074I1 (de) | 1993-03-05 | 2011-12-01 | Bayer Healthcare Ag | Humane monoklonale anti-TNF alpha Antikorper. |
CA2139385C (en) | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
AU697387C (en) | 1994-09-16 | 2006-03-02 | Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 | Polypeptides with Fc binding ability |
US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
CN1146442C (zh) | 1995-01-26 | 2004-04-21 | 拜奥根有限公司 | 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体 |
IL116784A (en) | 1996-01-16 | 2000-01-31 | Hadasit Med Res Service | Device for examining viscoelasticity of a living or artificial tissue |
US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
US20060269558A1 (en) | 1998-04-27 | 2006-11-30 | Murphy Gerald P | Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
DE60042617D1 (de) | 1999-01-07 | 2009-09-03 | Zymogenetics Inc | Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2 |
MXPA01008936A (es) | 1999-03-04 | 2003-07-21 | Human Genome Sciences Inc | Receptores 6 alfa y 6 beta del factor de necrosis tumoral. |
EP1161261A1 (en) | 1999-03-11 | 2001-12-12 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii and methods of use |
DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
US7262005B1 (en) | 2000-02-04 | 2007-08-28 | Aurora Biosciences Corporation | Methods of protein destabilization and uses thereof |
CN100390288C (zh) | 2000-04-11 | 2008-05-28 | 杰南技术公司 | 多价抗体及其应用 |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
AU2001272978A1 (en) | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel co-stimulatory molecules |
JP2004502450A (ja) | 2000-07-10 | 2004-01-29 | ノバルティス アクチエンゲゼルシャフト | ターゲッティング遺伝子送達のための二官能性分子およびそれと複合化されたベクター |
WO2002102303A2 (en) | 2001-05-01 | 2002-12-27 | Medimmune, Inc. | Crystals and structure of synagis fab |
US7115717B2 (en) | 2001-05-18 | 2006-10-03 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
US20050214210A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
JP4181032B2 (ja) | 2001-05-25 | 2008-11-12 | アムジェン インコーポレーテッド | B7関連タンパク質−2分子およびその使用 |
AU2002318364A1 (en) | 2001-06-14 | 2003-01-02 | Bristol-Myers Squibb Company | Novel human histone deacetylases |
US20030180296A1 (en) | 2001-12-20 | 2003-09-25 | Theodora Salcedo | Antibodies that immunospecifically bind to trail receptors |
PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
GB0220205D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Neisseria toxin |
BR0316737A (pt) | 2002-11-27 | 2005-12-13 | Irm Llc | Métodos e composições para induzir apoptose em células cancerosas |
AU2003303889A1 (en) | 2003-01-07 | 2004-08-30 | Biomerieux | Polypeptides f' of the hepatitis c virus, epitopes, and the diagnostic and therapeutic applications thereof |
TW200510532A (en) | 2003-07-15 | 2005-03-16 | Chugai Pharmaceutical Co Ltd | IgM production by transformed cell and method of quantifying the same |
WO2005011720A1 (en) | 2003-08-01 | 2005-02-10 | Enhan Technology Holdings International Co., Ltd. | Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury and proliferation and/or differentiation of neural stem cells in injured spinal cord |
CN100427505C (zh) | 2004-08-19 | 2008-10-22 | 中国医学科学院基础医学研究所 | 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体(ad5-10)及其制法与用途 |
JP2008519030A (ja) | 2004-11-05 | 2008-06-05 | パリンゲン インコーポレーテッド | 抗体で誘導される細胞膜損傷 |
WO2006063067A2 (en) | 2004-12-09 | 2006-06-15 | La Jolla Institute For Allergy And Immunology | Novel tnf receptor regulatory domain |
EP2361926A3 (en) | 2005-01-21 | 2011-12-21 | Epitopix, LLC | Yersinia SSP. polypeptides and methods of use |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
US20060269556A1 (en) | 2005-04-18 | 2006-11-30 | Karl Nocka | Mast cell activation using siglec 6 antibodies |
PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
US8088908B2 (en) | 2005-05-10 | 2012-01-03 | City Of Hope | Humanized anti-prostate stem cell antigen monoclonal antibody |
US20060269567A1 (en) | 2005-05-16 | 2006-11-30 | Liu Yuen | Universal detoxifying composition |
US20060269569A1 (en) | 2005-05-16 | 2006-11-30 | Liu Yuen | Universal antioncotic and pain relieving ointment |
CA2609173C (en) | 2005-05-24 | 2015-03-17 | The United States Of America As Represented By The Secretary Of The Navy Naval Medical Research Center, Code 00L | Anti-class 5 fimbrial adhesin-based passive immunoprophylactic |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
AR058983A1 (es) | 2006-01-13 | 2008-03-05 | Irm Llc | Metodos y composiciones para el tratamiento de enfermedades alergicas |
CN101074261A (zh) | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
US8268635B2 (en) | 2006-05-19 | 2012-09-18 | Antonio Ferrante | Methods of identifying agents that selectively activate p38 and/or NKkB signaling |
SG172698A1 (en) | 2006-06-12 | 2011-07-28 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
KR100847010B1 (ko) | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (dr5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
RU2472807C2 (ru) | 2006-09-08 | 2013-01-20 | Эбботт Лэборетриз | Интерлейкин-13-связывающие белки |
GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
KR20090105913A (ko) | 2006-11-02 | 2009-10-07 | 다니엘 제이 카폰 | 이동 부분을 갖는 하이브리드 면역글로불린 |
US20120039870A9 (en) | 2007-09-07 | 2012-02-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
CA2706700A1 (en) | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
WO2009106073A2 (en) | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
KR101196514B1 (ko) | 2008-08-01 | 2012-11-01 | 가부시키가이샤 아크시스 | 변형성 관절증 치료제 또는 예방제 |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
WO2011116387A1 (en) | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
SG184473A1 (en) | 2010-04-07 | 2012-11-29 | Abbvie Inc | Tnf-alpha binding proteins |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
SG189456A1 (en) | 2010-10-29 | 2013-05-31 | Daiichi Sankyo Co Ltd | Novel anti-dr5 antibody |
US20120195900A1 (en) | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
DK2699601T3 (en) | 2011-04-21 | 2018-04-23 | Bristol Myers Squibb Co | ANTIBODY POLYPEPTIDES ANTAGONIZING CD40 |
GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
US9382319B2 (en) * | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
EP2760891B1 (en) * | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
EP2771361A1 (en) | 2011-10-24 | 2014-09-03 | AbbVie Inc. | Bispecific immunobinders directed against tnf and il-17 |
JP6335796B2 (ja) | 2012-02-08 | 2018-06-06 | アイジーエム バイオサイエンシズ インク.Igm Biosciences Inc. | Cdim結合タンパク質及びその使用 |
EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
EP3415167B1 (en) | 2012-08-01 | 2024-05-29 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
IN2015DN01361A (sl) | 2012-08-02 | 2015-07-03 | Jn Biosciences Llc | |
US9725517B2 (en) | 2012-10-26 | 2017-08-08 | Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences | Humanized monoclonal antibodies against the extracellular domain of human death receptor 5 |
US9487773B2 (en) | 2013-03-01 | 2016-11-08 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Cell-based methods for coupling protein interactions and binding molecule selection |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
CA2907597A1 (en) * | 2013-05-07 | 2014-11-13 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules |
US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
CA2922830A1 (en) | 2013-09-05 | 2015-04-16 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
CA2931641C (en) | 2013-12-30 | 2022-05-10 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
SG11201605691VA (en) | 2014-01-16 | 2016-08-30 | Mario Umberto Francesco Mondelli | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen |
CN105992772A (zh) | 2014-02-10 | 2016-10-05 | Igm生命科学股份有限公司 | IgA多特异性结合分子 |
WO2015145360A1 (en) | 2014-03-24 | 2015-10-01 | Glennie Martin J | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
SI3560954T1 (sl) | 2014-04-03 | 2021-11-30 | Igm Biosciences, Inc. | Spremenjena J-veriga |
EP3204412B1 (en) | 2014-10-08 | 2020-08-19 | F.Hoffmann-La Roche Ag | Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents |
ES2806500T3 (es) | 2015-01-20 | 2021-02-17 | Igm Biosciences Inc | Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas |
SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | CD20 binding compounds and their uses |
EP3274051A4 (en) | 2015-03-25 | 2018-08-22 | IGM Biosciences A/S | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
JP6811723B2 (ja) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 |
EP3317297A4 (en) | 2015-06-30 | 2019-03-20 | Sanford-Burnham Medical Research Institute | BTLA AGONIST FUSION PROTEIN AND USES THEREOF |
EP3319936A4 (en) | 2015-07-12 | 2019-02-06 | Suzhou M-conj Biotech Co., Ltd. | PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES |
DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
CN108463245A (zh) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j链的结合分子 |
HUE055972T2 (hu) | 2016-05-09 | 2022-01-28 | Igm Biosciences Inc | Anti-PD-L1 antitestek |
EP3487533A4 (en) | 2016-07-20 | 2020-03-25 | IGM Biosciences, Inc. | MULTIMERE OX40-BINDING MOLECULES AND USES THEREOF |
WO2018017889A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
EP3487298A4 (en) | 2016-07-20 | 2020-03-11 | IGM Biosciences, Inc. | MOLECULES FIXING PDK137 / 4 AND USES THEREOF |
US20190338041A1 (en) | 2016-07-20 | 2019-11-07 | Igm Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
JP7305538B2 (ja) | 2016-09-23 | 2023-07-10 | メルス ナムローゼ フェンノートシャップ | 細胞によって発現される生物活性を調節する結合分子 |
EP3607091A4 (en) | 2017-04-07 | 2021-01-20 | IGM Biosciences, Inc. | MODIFIED HUMAN CONSTANT IGM REGIONS FOR THE MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION |
KR20200123782A (ko) | 2018-02-26 | 2020-10-30 | 아이쥐엠 바이오사이언스 인코포레이티드 | 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도 |
MX2020009069A (es) | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
AU2019368289A1 (en) | 2018-10-23 | 2021-04-29 | Igm Biosciences, Inc. | Multivalent IgM- and IgA-Fc-based binding molecules |
US20220106398A1 (en) | 2019-02-08 | 2022-04-07 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
US20230203119A1 (en) | 2019-08-15 | 2023-06-29 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
KR20220045030A (ko) | 2019-08-17 | 2022-04-12 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도 |
CN114269380A (zh) | 2019-08-23 | 2022-04-01 | Igm生物科学股份有限公司 | IgM糖变体 |
JP2022549186A (ja) | 2019-09-19 | 2022-11-24 | アイジーエム バイオサイエンシズ インコーポレイテッド | 高い標的密度の細胞に対する選択性を向上させた多量体抗体 |
BR112022013071A2 (pt) | 2020-01-06 | 2022-09-20 | Igm Biosciences Inc | Moléculas de ligação multiméricas altamente sialiladas |
CN115485299A (zh) | 2020-04-22 | 2022-12-16 | Igm生物科学股份有限公司 | Pd-1激动剂多聚结合分子 |
JP2023526224A (ja) | 2020-05-12 | 2023-06-21 | アイジーエム バイオサイエンシズ インコーポレイテッド | がんを治療するための、がん治療薬との組合せでの多量体抗dr5結合分子の使用 |
WO2022026475A2 (en) | 2020-07-27 | 2022-02-03 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
WO2022109023A1 (en) | 2020-11-17 | 2022-05-27 | Igm Biosciences, Inc. | Uses of effector cell engaging molecules with moieties of differing potencies |
CA3205834A1 (en) | 2021-02-17 | 2022-08-25 | Paul R. Hinton | Anti-cd123 binding molecules and uses thereof |
WO2022177870A1 (en) | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
-
2016
- 2016-01-20 ES ES16740686T patent/ES2806500T3/es active Active
- 2016-01-20 US US15/544,873 patent/US10689449B2/en active Active
- 2016-01-20 JP JP2017556795A patent/JP7179464B2/ja active Active
- 2016-01-20 CA CA2972990A patent/CA2972990A1/en active Pending
- 2016-01-20 SG SG11201705116SA patent/SG11201705116SA/en unknown
- 2016-01-20 CN CN201680006321.XA patent/CN107207601A/zh active Pending
- 2016-01-20 WO PCT/US2016/014153 patent/WO2016118641A1/en active Application Filing
- 2016-01-20 IL IL308212A patent/IL308212A/en unknown
- 2016-01-20 PL PL16740686T patent/PL3247728T3/pl unknown
- 2016-01-20 EP EP16740686.7A patent/EP3247728B1/en active Active
- 2016-01-20 EP EP20168740.7A patent/EP3750918A1/en active Pending
- 2016-01-20 SG SG10202001779UA patent/SG10202001779UA/en unknown
- 2016-01-20 NZ NZ732922A patent/NZ732922A/en unknown
- 2016-01-20 SI SI201630842T patent/SI3247728T1/sl unknown
- 2016-01-20 KR KR1020177022773A patent/KR102435324B1/ko active IP Right Grant
- 2016-01-20 AU AU2016209324A patent/AU2016209324B2/en active Active
- 2016-01-20 DK DK16740686.7T patent/DK3247728T3/da active
- 2016-01-20 PT PT167406867T patent/PT3247728T/pt unknown
- 2016-01-20 HU HUE16740686A patent/HUE051013T2/hu unknown
- 2016-01-20 IL IL284430A patent/IL284430B2/en unknown
-
2017
- 2017-06-21 IL IL253054A patent/IL253054B/en unknown
- 2017-06-30 US US15/638,748 patent/US9938347B2/en active Active
-
2020
- 2020-02-24 AU AU2020201323A patent/AU2020201323B2/en active Active
- 2020-04-28 US US16/861,102 patent/US11578131B2/en active Active
- 2020-09-23 JP JP2020158581A patent/JP2021006044A/ja active Pending
-
2022
- 2022-09-07 JP JP2022142258A patent/JP7499813B2/ja active Active
- 2022-11-14 US US18/055,340 patent/US20230203173A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284430A (en) | Tumor necrosis factor-α receptor binding molecules and their uses | |
IL259399A (en) | Antibodies against glucocorticoid-induced tumor necrosis factor receptors (gitr) and their uses | |
HK1252957A1 (zh) | TGF-β超家族I型和II型受體異多聚體及其用途 | |
ZA201704797B (en) | Agonistic tnf receptor binding agents | |
IL263799A (en) | Multimeric ox40 binding molecules and uses thereof | |
IL248945B (en) | Antibodies against glucocorticoids that induce tumor necrosis factor receptor (gitr) and their uses | |
IL254223A (en) | CD20 binding compounds and their uses | |
SG10202111844VA (en) | Cxcr4 binding molecules | |
GB201811410D0 (en) | OX40 Binding molecules | |
EP3315513A4 (en) | Cd154 binding polypeptide and use thereof | |
IL259883A (en) | Antibody molecules that bind tnf alpha | |
IL272798A (en) | TNF receptor binding agonists |